Jaymin Upadhyay

Dr. Jaymin Upadhyay


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
MCMariesa Cay
Mariesa Cay
JGJoseph Gonzalez-Heydrich
Joseph Gonzalez-Heydrich
MTMartin H Teicher
Martin H Teicher
HHHanne van der Heijden
Hanne van der Heijden
DODost Ongur
Dost Ongur
JUJaymin Upadhyay
Jaymin Upadhyay

10 February 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
ATAnthony Tucker-Bartley
Anthony Tucker-Bartley
JLJordan Lemme
Jordan Lemme
AGAndrea Gomez-Morad
Andrea Gomez-Morad
NSNehal Shah
Nehal Shah
MVMiranda Veliu
Miranda Veliu
JUJaymin Upadhyay
Jaymin Upadhyay

1 September 2015 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
JUJaymin Upadhyay
Jaymin Upadhyay
JLJordan Lemme
Jordan Lemme
JAJulie Anderson
Julie Anderson
DBDavid Bleakman
David Bleakman
TLThomas Large
Thomas Large
LBLino Becerra
Lino Becerra

Verified
Journal Article
Open access
PDF file
ATAnthony Tucker-Bartley
Anthony Tucker-Bartley
DSDaryl J. Selen
Daryl J. Selen
EGEmma Golden
Emma Golden
RGRaquel van Gool
Raquel van Gool
DEDavid Ebb
David Ebb
JUJaymin Upadhyay
Jaymin Upadhyay
Fibrous dysplasia (FD) is a rare, non-inherited bone disease occurring following a somatic gain-of-function R201 missense mutation of the guanine-nucleotide binding protein alpha subunit stimulating activity polypeptide 1 (GNAS) gene. The spectrum of the disease ranges from a single FD lesion to a combination with extraskeletal features; an amalgamation with café-au-lait skin hyperpigmentation, precocious puberty, and other endocrinopathies defines McCune–Albright Syndrome (MAS). Pain in FD/MAS represents one of the most prominent aspects of the disease and one of the most challenging to treat—an outcome driven by (i) the heterogeneous nature of FD/MAS, (ii) the variable presentation of pain phenotypes (i.e., craniofacial vs. musculoskeletal pain), (iii) a lack of studies probing pain mechanisms, and (iv) a lack of rigorously validated analgesic strategies in FD/MAS. At present, a range of pharmacotherapies are prescribed to patients with FD/MAS to mitigate skeletal disease activity, as well as pain. We analyze evidence guiding the current use of bisphosphonates, denosumab, and other therapies in FD/MAS, and also discuss the potential underlying pharmacological mechanisms by which pain relief may be achieved. Furthermore, we highlight the range of presentation of pain in individual cases of FD/MAS to further describe the difficulties associated with employing effective pain treatment in FD/MAS. Potential next steps toward identifying and validating effective pain treatments in FD/MAS are discussed, such as employing randomized control trials and probing new pain pathways in this rare bone disease.


13 February 2019 in JBMR Plus
Verified
Journal Article
Open access
PDF file
KPKe Peng
Ke Peng
KCKin Cheung
Kin Cheung
ALArielle Lee
Arielle Lee
CSChristine Sieberg
Christine Sieberg
DBDavid Borsook
David Borsook
JUJaymin Upadhyay
Jaymin Upadhyay
Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare, inherited, connective tissue disease with ∼800 documented cases worldwide. The principal pathological feature of FOP is the transition of skeletal muscle, tendons, ligaments, and fascia into cartilage and bone. This heterotopic ossification (HO) is often preceded by painful soft tissue swellings or flare‐ups that may last several months. For many individuals, experiencing a flare‐up may represent a worsening of their condition and contribute to feelings of anxiety or suppressed affect, both of which are well‐recognized to exacerbate pain perception. To date, much remains unknown regarding the dynamics of pain and emotional health in FOP during flare‐up and also quiescent, non–flare‐up disease phases. In order to elucidate the occurrence and effect of pain in FOP, this study analyzed Patient‐Reported Outcomes Measurement Information System–based questionnaires completed by 99 patients participating in the international FOP Registry over a 30‐month period. We observed that although moderate to severe pain (≥4, 0 to 10 pain scale) was commonly associated with flare‐ups (56% to 67%), surprisingly, 30% to 55% of patients experienced similar pain levels during non–flare‐up states. In those patients reporting pain levels of ≥4, 45% to 74% of patients report experiencing anxiety, depression, or irritability, with 36% to 48% reporting emotional problems during no to mild pain states. Furthermore, independent of the flare‐up status, the severity of pain in FOP patients was found to be significantly anti‐correlated with emotional health, physical health, and overall quality‐of‐life. These findings strongly suggest the need for an improved understanding of pain and emotional health in FOP during flare‐up and quiescent periods. © 2019 The Authors.JBMR Pluspublished by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.